{
  "id": 10693300,
  "title": "AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push",
  "url": "https://urgent.news/2026/09/29/astrazeneca-invests-2b-in-summit-gaining-seat-at-the-table-for-pd-1",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-29T12:49:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/summit-astrazeneca-ivonescimab-deal-pd1-vegf/752865/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "AstraZeneca buys a $2B stake in Summit, taking equity in bet on cancer drug",
        "url": "https://urgent.news/2026/09/28/astrazeneca-buys-a-2b-stake-in-summit-taking-equity-in-bet-on-cancer",
        "published": "2026-09-28T22:22:39.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}